- Finch has 34 US and Foreign Patents in Its portfolio
- The Company has 60 patent applications pending
Finch Therapeutics Group, Inc announced on 7/25/18 that the U.S. Patent and Trademark Office (USPTO) has issued six new patents to Finch covering its Full-Spectrum Microbiota (FSM) and Rationally-Selected Microbiota (RSM) product platforms. The additional IP includes:
- U.S. Patent No. 10,022,406 broadly covers donor-derived compositions. It is solely owned by Finch and provides coverage until at least 2031.
- U.S. Patent No. 9,962,413 broadly covers the use of screened, healthy donors in the manufacture of microbial therapies. It is solely owned by Finch and provides coverage until at least 2031.
- U.S. Patent No. 9,901,603 broadly covers lyophilized formulations of microbial therapies. It is solely owned by Finch and provides coverage until at least 2036.
- U.S. Patent Nos. 9,968,638 and 10,028,980 broadly cover microbial therapies delivered via oral capsules. These patents are exclusively licensed from the Regents of the University of Minnesota and provide coverage through at least 2032.
- U.S. Patent No. 9,962,414 broadly covers pharmaceutical compositions containing a plurality of Clostridium species. It is solely owned by Finch and provides coverage until at least 2021.
“After more than 30 years of translational research developing microbial therapies for patients, I’m thrilled to see the latest additions to Finch’s patent estate which leave the Company uniquely positioned to continue to unlock the therapeutic potential of the microbiome,” said Tom Borody, M.D. who is a named inventor on 27 of Finch’s patents.”
Finch’s industry-leading patent portfolio consists of 34 issued U.S. and foreign patents and more than 60 pending patent applications, which have broad applicability across the microbiome field. Reflecting the early leadership of its founders in building this field, Finch’s patent portfolio includes composition of matter patents with priority dates as early as 2000, the earliest in the industry. This broad estate covers both FSM and RSM products, with issued claims covering pharmaceutical compositions containing bacterial strains of the genus Clostridium among other important composition of matter and method of use claims.